Acetazolamide - Revision history

Danbot: Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T21:55:41Z

Switch SMW query from broadtable to table format for better layout with TOC

← Revisión anterior		Revisión del 21:55 20 mar 2026
Línea 141:		Línea 141:
	\|?Has Route=Route		\|?Has Route=Route
	\|?Has Population=Population		\|?Has Population=Population
	\|format=~~broadtable~~		\|format=table
	\|headers=plain		\|headers=plain
	\|mainlabel=-		\|mainlabel=-

Danbot: Add SMW Indications by Condition query table

2026-03-20T18:33:47Z

Add SMW Indications by Condition query table

← Revisión anterior		Revisión del 18:33 20 mar 2026
Línea 131:		Línea 131:

	==Comments==		==Comments==

			==Indications by Condition==
			''The following table is automatically generated from disease/condition pages across WikEM.''

			{{#ask:[[Has DrugName::Acetazolamide]]
			\|?Has Indication=Indication
			\|?Has Dose=Dose
			\|?Has Context=Context
			\|?Has Route=Route
			\|?Has Population=Population
			\|format=broadtable
			\|headers=plain
			\|mainlabel=-
			\|sort=Has Indication
			\|limit=50
			}}


	==See Also==		==See Also==

Fletc151: /* References */

2019-06-06T15:55:07Z

References

← Revisión anterior		Revisión del 15:55 6 jun 2019
Línea 32:		Línea 32:
	*8-30mg/kg/day PO QD		*8-30mg/kg/day PO QD
	*Do not exceed 30mg/kg/day or 1g/day		*Do not exceed 30mg/kg/day or 1g/day

			===Off-label use===
			*Familial periodic paralysis; Hydrocephalus, normal-pressure; Idiopathic intracranial hypertension; Metabolic alkalosis; Prevention of cystine renal calculi (adjunctive therapy); Respiratory stimulant in stable hypercapnic COPD

	==Pediatric Dosing==		==Pediatric Dosing==
Línea 56:		Línea 59:
	**Adult: contraindicated in significant impairment/cirrhosis		**Adult: contraindicated in significant impairment/cirrhosis
	**Pediatric: contraindicated in significant impairment/cirrhosis		**Pediatric: contraindicated in significant impairment/cirrhosis
			**Geriatric: Refer to adult dosing. Oral: Initial doses should begin at the low end of the dosage range.

	==Contraindications==		==Contraindications==
Línea 132:		Línea 136:
	==References==		==References==
	<references/>		<references/>
			*Acetazolamide injection [prescribing information]. Big Flats, NY: X-Gen Pharmaceuticals, Inc; October 2015.
	[[Category:Pharmacology]]		[[Category:Pharmacology]]

Rossdonaldson1: /* Prophylaxis */

2018-04-19T03:42:01Z

Prophylaxis

← Revisión anterior		Revisión del 03:42 19 abr 2018
Línea 45:		Línea 45:
	====Prophylaxis====		====Prophylaxis====
	*2.5mg/kg/dose (maximum 125mg/dose) PO every 12 hours<ref>Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society Practice Guidelines for the Prevention and Treatment of Acute Altitude Illness: 2014 Update. Wilderness & Environmental Medicine. 2014(25): S4–S14)</ref>		*2.5mg/kg/dose (maximum 125mg/dose) PO every 12 hours<ref>Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society Practice Guidelines for the Prevention and Treatment of Acute Altitude Illness: 2014 Update. Wilderness & Environmental Medicine. 2014(25): S4–S14)</ref>
			*Start 24hr before ascent and continue for the first 48hrs at peak altitude

	==Special Populations==		==Special Populations==

Rossdonaldson1: /* Prophylaxis */

2018-04-19T03:41:35Z

Prophylaxis

← Revisión anterior		Revisión del 03:41 19 abr 2018
Línea 20:		Línea 20:
	====Prophylaxis====		====Prophylaxis====
	*125mg PO BID<ref>Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society Practice Guidelines for the Prevention and Treatment of Acute Altitude Illness: 2014 Update. Wilderness & Environmental Medicine. 2014(25): S4–S14)</ref>		*125mg PO BID<ref>Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society Practice Guidelines for the Prevention and Treatment of Acute Altitude Illness: 2014 Update. Wilderness & Environmental Medicine. 2014(25): S4–S14)</ref>
			*Start 24hr before ascent and continue for the first 48hrs at peak altitude

	===[[CHF]]-associated Edema===		===[[CHF]]-associated Edema===

Rossdonaldson1: /* Acute altitude sickness */

2018-04-19T03:39:20Z

Acute altitude sickness

← Revisión anterior		Revisión del 03:39 19 abr 2018
Línea 38:		Línea 38:

	===[[Acute altitude sickness]]===		===[[Acute altitude sickness]]===
			====Treatment====
	*<12 years: safety and efficacy not established		*<12 years: safety and efficacy not established
	*>12 years: 500-1000mg PO QD		*>12 years: 500-1000mg PO QD

			====Prophylaxis====
			*2.5mg/kg/dose (maximum 125mg/dose) PO every 12 hours<ref>Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society Practice Guidelines for the Prevention and Treatment of Acute Altitude Illness: 2014 Update. Wilderness & Environmental Medicine. 2014(25): S4–S14)</ref>

	==Special Populations==		==Special Populations==

Rossdonaldson1: /* Acute altitude sickness */

2018-04-19T03:37:38Z

Acute altitude sickness

← Revisión anterior		Revisión del 03:37 19 abr 2018
Línea 14:		Línea 14:

	===[[Acute altitude sickness]]===		===[[Acute altitude sickness]]===
			====Treatment====
	*500-1000mg extended release PO QD		*500-1000mg extended release PO QD
	*Continue treatment for 48 hours or longer if necessary		*Continue treatment for 48 hours or longer if necessary

			====Prophylaxis====
			*125mg PO BID<ref>Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society Practice Guidelines for the Prevention and Treatment of Acute Altitude Illness: 2014 Update. Wilderness & Environmental Medicine. 2014(25): S4–S14)</ref>

	===[[CHF]]-associated Edema===		===[[CHF]]-associated Edema===

Mholtz: Text replacement - "qd" to "QD"

2017-07-07T07:38:06Z

Text replacement - "qd" to "QD"

← Revisión anterior		Revisión del 07:38 7 jul 2017
Línea 10:		Línea 10:
	**500mg PO q12h (sustained release)		**500mg PO q12h (sustained release)
	*Open-angle Glucoma:		*Open-angle Glucoma:
	**250mg-1g PO/IV qd		**250mg-1g PO/IV QD
	**500mg PO q12h (sustained release)		**500mg PO q12h (sustained release)

	===[[Acute altitude sickness]]===		===[[Acute altitude sickness]]===
	*500-1000mg extended release PO qd		*500-1000mg extended release PO QD
	*Continue treatment for 48 hours or longer if necessary		*Continue treatment for 48 hours or longer if necessary

Línea 25:		Línea 25:

	===[[Epilepsy]]===		===[[Epilepsy]]===
	*8-30mg/kg/day PO qd		*8-30mg/kg/day PO QD
	*Do not exceed 30mg/kg/day or 1g/day		*Do not exceed 30mg/kg/day or 1g/day

Línea 31:		Línea 31:
	===Epilepsy===		===Epilepsy===
	*<12 years: safety and efficacy not established		*<12 years: safety and efficacy not established
	*>12 years: 8-30mg/kg/day PO qd		*>12 years: 8-30mg/kg/day PO QD

	===[[Acute altitude sickness]]===		===[[Acute altitude sickness]]===
	*<12 years: safety and efficacy not established		*<12 years: safety and efficacy not established
	*>12 years: 500-1000mg PO qd		*>12 years: 500-1000mg PO QD

	==Special Populations==		==Special Populations==

Neil.m.young: Text replacement - "0 mg" to "0mg"

2016-07-19T09:44:16Z

Text replacement - "0 mg" to "0mg"

← Revisión anterior		Revisión del 09:44 19 jul 2016
Línea 7:		Línea 7:
	===[[Glaucoma]]===		===[[Glaucoma]]===
	*Closed-angle Glaucoma:		*Closed-angle Glaucoma:
	**500mg PO/IV, followed by 125-~~250 mg~~ PO q4h		**500mg PO/IV, followed by 125-250mg PO q4h
	**500mg PO q12h (sustained release)		**500mg PO q12h (sustained release)
	*Open-angle Glucoma:		*Open-angle Glucoma:
Línea 25:		Línea 25:

	===[[Epilepsy]]===		===[[Epilepsy]]===
	*8-~~30 mg~~/kg/day PO qd		*8-30mg/kg/day PO qd
	*Do not exceed 30mg/kg/day or 1g/day		*Do not exceed 30mg/kg/day or 1g/day

Línea 31:		Línea 31:
	===Epilepsy===		===Epilepsy===
	*<12 years: safety and efficacy not established		*<12 years: safety and efficacy not established
	*>12 years: 8-~~30 mg~~/kg/day PO qd		*>12 years: 8-30mg/kg/day PO qd

	===[[Acute altitude sickness]]===		===[[Acute altitude sickness]]===
	*<12 years: safety and efficacy not established		*<12 years: safety and efficacy not established
	*>12 years: 500-~~1000 mg~~ PO qd		*>12 years: 500-1000mg PO qd

	==Special Populations==		==Special Populations==

Rossdonaldson1: Text replacement - "tx" to "treatment"

2016-07-15T00:20:10Z

Text replacement - "tx" to "treatment"

← Revisión anterior		Revisión del 00:20 15 jul 2016
Línea 59:		Línea 59:
	*glaucoma, angle-closure (long-term use)		*glaucoma, angle-closure (long-term use)
	*caution if hypersensitivity to sulfonamides		*caution if hypersensitivity to sulfonamides
	*caution if ASA tx, high-dose		*caution if ASA treatment, high-dose
	*caution if hepatic impairment		*caution if hepatic impairment
	*caution if pulmonary impairment		*caution if pulmonary impairment